iCAD (ICAD) Stock Price, News & Analysis

Company Overview

iCAD, Inc. engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.

Key Stats

• Today's Range: $1.47 to $1.57
• 50-Day Range: $1.39 to $2.40
• 52-Week Range: $1.18 to $2.65
• Volume: 365,136 shs
• Average Volume: 265,472 shs
• Market Capitalization: $41.00 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

iCAD Stock Analysis - MarketRank™

iCAD scored higher than 10% of companies evaluated by MarketBeat, and ranked 623rd out of 651 stocks in the computer and technology sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for iCAD.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of iCAD is -11.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of iCAD is -11.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

iCAD has a P/B Ratio of 1.39. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.99% of the float of iCAD has been sold short.

Short Interest Ratio / Days to Cover

iCAD has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in iCAD has recently increased by 5.73%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

iCAD does not currently pay a dividend.

Dividend Growth

iCAD does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.99% of the float of iCAD has been sold short.

Short Interest Ratio / Days to Cover

iCAD has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in iCAD has recently increased by 5.73%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.32

News Sentiment

iCAD has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Computer and Technology companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for iCAD this week, compared to 2 articles on an average week.

Search Interest

4 people have searched for ICAD on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added iCAD to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, iCAD insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.29% of the stock of iCAD is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 24.61% of the stock of iCAD is held by institutions.

ICAD Stock Analysis - Frequently Asked Questions

How have ICAD shares performed this year?

iCAD's stock was trading at $1.77 on January 1st, 2024. Since then, ICAD stock has decreased by 12.7% and is now trading at $1.5450.
View the best growth stocks for 2024 here.

How were iCAD's earnings last quarter?

iCAD, Inc. (NASDAQ:ICAD) announced its quarterly earnings data on Tuesday, November, 9th. The technology company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.08) by $0.01. The technology company had revenue of $9.36 million for the quarter, compared to analyst estimates of $9.41 million. iCAD had a negative trailing twelve-month return on equity of 15.65% and a negative net margin of 17.81%.

Who are iCAD's major shareholders?

Top institutional investors of iCAD include Greenwood Capital Associates LLC (1.11%), Essex LLC (0.52%) and Captrust Financial Advisors (0.08%). Insiders that own company stock include Jonathan Go, Dana R Brown, Andy Sassine, Timothy Norris Irish, Michael S Klein, Charles Ross Carter and Susan Alyson Wood.
View institutional ownership trends.

How do I buy shares of iCAD?

Shares of ICAD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of iCAD own?

Based on aggregate information from My MarketBeat watchlists, some other companies that iCAD investors own include Enovix (ENVX), Globant (GLOB), Rambus (RMBS), Luminar Technologies (LAZR), Toast (TOST), COMPASS Pathways (CMPS) and Ginkgo Bioworks (DNA).

Company Calendar

• Last Earnings: 11/09/2021
• Today: 11/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Computer and Technology
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:ICAD
• CUSIP: N/A
• CIK: 749660
• Web: www.icadmed.com
• Phone: (603) 882-5200
• Fax: 603-880-3843
• Employees: 67
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.13)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-4,850,000.00
• Net Margins: -17.81%
• Pretax Margin: -27.87%
• Return on Equity: -15.65%
• Return on Assets: -12.52%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.02
• Quick Ratio: 3.91

Sales & Book Value

• Annual Sales: $17.32 million
• Price / Sales: 2.37
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.11 per share
• Price / Book: 1.39

Miscellaneous

• Outstanding Shares: 26,540,000
• Free Float: 23,809,000
• Market Cap: $41.00 million
• Optionable: Optionable
• Beta: 1.47